The Research & Development phase for µMESH began in 2021, supported by non-dilutive funding from the EU government, and continues today with unwavering support from various governmental agencies and research foundations, both in the EU and the US
​
To date, µMESH research activities have totaled over $3.0M
​​​
Two major peer-reviewed publications have already been published, detailing the properties and therapeutic efficacy of µMESH in rigorous preclinical models​
July 2021
Conformable hierarchically engineered polymeric micromeshes enabling combinatorial therapies in brain tumours
July 2023
μMESH-Enabled Sustained Delivery of Molecular and Nanoformulated Drugs for Glioblastoma Treatment
January 2022
iMESH - a microMESH-based therapeutic approach for children with brain cancer
2022 SPARK Award in Translational Research
July 2022
Preclinical validation and market analysis of a microMESH implant for brain cancer eradication
European Research Council (ERC)
Proof of Concept grant - Call 2022
January 2025
microGRID-enabled Sustained Delivery of Chemotherapeutic and Disconnecting agents to Eradicate high-grade Gliomas
​Further research is ongoing, with collaborative efforts expanding both within the institutions of the founding team (Italian Institute of Technology, Stanford University, and MD Anderson Cancer Center) and with hospitals and biomedical research institutions in Europe, the US, and Australia
​​
Chiromesh Therapeutics, Inc. welcomes new partnerships to strengthen its commitment to transforming the lives of patients and families facing incurable malignancies